Suspension of rimonabant by the EMEA

Practical Diabetes International

Volumn 25, Issue 9, 2008, Pages 354-

  Haslam, David ^a  

^a National Obesity Forum   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLI; NON PRESCRIPTION DRUG; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; RIMONABANT; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

BLOOD PRESSURE; BOREDOM; CARDIOVASCULAR RISK; DIET THERAPY; DRUG EFFICACY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; IRRITABILITY; MEDICAL SOCIETY; MENTAL DISEASE; MOOD CHANGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; OVARY POLYCYSTIC DISEASE; PHYSICAL ACTIVITY; PULSE RATE; SIDE EFFECT; WEIGHT REDUCTION;

EID: 61749089500     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1305     Document Type: Note

References (1)

1. Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008; published online 23 October 2008. DOI:10.1016/ S0140-6736(08)61525-1.